Terms and Conditions

World Pharma News Portal (the "Portal") is a web based news platform maintained by DAVID eHealth & Pharma UG ("Administrator", "Editor" "we," or “us”).

Terms of Use

We are not responsible for published news release, announce and any other related multimedia content (“News Content") in any way, including without limitation, any copyright, trademark, publicity, privacy, contract or other rights clearance, or the accuracy, timeliness, integrity, quality, safety, appropriateness or other aspect of any information or other content contained therein. You are solely responsible for verifying the accuracy and completeness of News Content, and for determining if any permissions are necessary to use the News Content, and, if so, for securing those permissions prior to your use of the New Content. If you choose to rely on or otherwise use News Content in any way you do so solely at your own risk and without any representation or warranty whatsoever from us.

Disclaimer Notice

The Portal includes pharmaceutical related information, news and resources on which it is operated or contained, which is made available by the Project Administrator and Portal Partners, Contributors. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them.

However we accepts no responsibility or liability whatsoever with regard to the material on this site. This material is:

  • Information of a general nature only which is not intended to address the specific circumstances of any particular individual or entity
  • Not necessarily comprehensive, complete, accurate or up to date
  • Sometimes linked to external sites over which we have no control and for which we assumes no responsibility

Please note that it cannot be guaranteed that a document available online exactly reproduces an officially adopted text. It is our goal to minimise disruption caused by technical errors. However some data or information on Portal may have been created or structured in files or formats that are not error-free and we cannot guarantee that our service will not be interrupted or otherwise affected by such problems. We accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.

Copyright Notice

This World Wide Web site includes information, and the software and media on which it is operated or contained, individually and collectively known as the "Information" which include RSS, Web Links and News made available by us.

The Information has been supplied by us and portal Partners, Contributors, and/or by companies or organisations involved in Pharmaceutical business, research and development activities (the "Information Suppliers"). All title and intellectual property rights, including, but not limited to, trademarks, copyrights in and to the Information, and any copies thereof in whatever form, are owned by the Information Suppliers, and/or by the Portal Administrator, and/or by other parties, and are protected by the applicable laws. Any trademarks or names being used are for editorial purposes only, and to the benefit of the trademark owner, with no intention of infringing upon that trademark.

Except where otherwise noted, all site contents are:
© World Pharma News.

Reproduction is authorised, provided its source "World Pharma News" or "www.worldpharmanews.com" (with web link to http://www.worldpharmanews.com) is acknowledged.

Advertising

On the Portal, the editorial content and process are always clearly separated from advertising. Advertising spaces such as banners (images or texts) are clearly marked or separated. Likewise, any content provided by an advertising sponsor is clearly marked as such, and is physically separated from editorial content. We are also selective in the advertising we accept. Our main advertising policies are as follows:
  • We will clearly distinguish advertising from Pharmaceutical and Health information content, using identifying words, design, or placement. We design our web sites to avoid confusion between advertising and healthcare information content.
  • Under no circumstances acceptance of an advertisement will be considered a Portal endorsement of the product(s) or the company advertised.

Please note that Portal Administrator will consider, within appropriate editorial context, all critics related to the advertisements or our Advertising Policy.

Personal Data Protection Policy

We are committed to user privacy. To better protect your privacy, we provide this notice explaining our on-line information practices and the choices you can make about the way your information is collected and used by us.

You can browse freely through most of the Portal without giving any information about yourself. However, in some cases, personal information may be required in order to enable us to provide the e-services you request. Please note that we collect no personal information about you when you visit our Web site unless you choose to provide that information to us.

Data Protection by Third-party Sites

Some Portal Web pages contain links to other sites whose information practices may be different to those of World Pharma News. We encourage you to read the privacy statements on other Web sites you visit, as we have no control over information that is submitted to, or collected by, these third parties.

Log files

Log files allow us to record visitors' use of the site. We puts together log file information from all our visitors, which we use to improve our understanding of user needs and patterns of behavior, and to make improvements to the layout of the site and to the information in it, based on the way that visitors move around it. Log files do not contain any personal information about you. We automatically collect non-personal information such as:
  • The type and version of the operating system of your computer
  • The type and version of the browser used to access our Portal.
  • The Internet domain.
  • The IP address from which you access our Portal.
  • The date and time you access our Portal.
  • The pages you visit.
  • If you linked to our Portal from another Web site, the address of that Web site.

If this Privacy Notice changes in any way, we will place an updated version on this page. Regularly reviewing this page ensures that you are always aware of what information we collect, how we use it and under what circumstances, if any, we will share it with other parties.

In case of further questions, comments or suggestions regarding above Privacy Notice please don't hesitate to contact us.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...